相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy (vol 13, 8, 2014)
Heng Li et al.
MOLECULAR CANCER (2022)
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Elaine Chang et al.
CLINICAL CANCER RESEARCH (2021)
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J. Crabb et al.
CLINICAL CANCER RESEARCH (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN
Guang Shan et al.
CELLULAR ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Sequentially stimuli-responsive anticancer nanomedicines
Lingyu Wei et al.
NANOMEDICINE (2021)
Lymphatic metastasis of bladder cancer: Molecular mechanisms, diagnosis and targeted therapy
Sen Liu et al.
CANCER LETTERS (2021)
Precision medicine in breast cancer: From clinical trials to clinical practice
Edoardo Crimini et al.
CANCER TREATMENT REVIEWS (2021)
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T. Tagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
Hui Zhang et al.
MOLECULAR CANCER (2021)
Precision oncology in metastatic colorectal cancer - from biology to medicine
Federica Di Nicolantonio et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Tumor microenvironment as a therapeutic target in cancer
Yi Xiao et al.
PHARMACOLOGY & THERAPEUTICS (2021)
A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer
Weimei Ruan et al.
CLINICAL EPIGENETICS (2021)
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P. Grivas et al.
BMC CANCER (2021)
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
Petros Grivas et al.
CANCER TREATMENT REVIEWS (2021)
Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer
Jingtong Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy
Marine M. Leblond et al.
CANCERS (2021)
Advances in bladder cancer biology and therapy
Linda Tran et al.
NATURE REVIEWS CANCER (2021)
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models
Chi-Ping Huang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer
Qianghua Zhou et al.
THERANOSTICS (2021)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET ONCOLOGY (2020)
Blockade of DC-SIGNthorn Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer
Baoying Hu et al.
CANCER RESEARCH (2020)
Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion
Jinbo Chen et al.
EMBO REPORTS (2020)
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Jonathan Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bladder Cancer. Version 3.2020
Thomas W. Flaig et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
FGF9 inhibition by a novel binding peptide has efficacy in gastric and bladder cancer per se and reverses resistance to cisplatin
Jizhong Wang et al.
PHARMACOLOGICAL RESEARCH (2020)
Intravesical Hydrogels as Drug Reservoirs
Heping Qiu et al.
TRENDS IN BIOTECHNOLOGY (2020)
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity
Yiwen Lu et al.
CELL (2020)
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Hye Won Lee et al.
GENOME MEDICINE (2020)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Photoactivated H2 Nanogenerator for Enhanced Chemotherapy of Bladder Cancer
Rui Sun et al.
ACS NANO (2020)
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
Rafael Morales-Barrera et al.
CANCER TREATMENT REVIEWS (2020)
Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
Xu Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma
Zhaohui Chen et al.
NATURE COMMUNICATIONS (2020)
Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
Yi-Ting Chen et al.
CANCERS (2020)
Bladder Cancer: A Review
Andrew T. Lenis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients
JungHo Kong et al.
NATURE COMMUNICATIONS (2020)
An ATF(24) peptide-functionalized beta-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment
Bingtao Zhai et al.
CANCER BIOLOGY & MEDICINE (2020)
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Qiang Li et al.
CLINICAL CANCER RESEARCH (2019)
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer
Georgios Kallifatidis et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells
Mingqing Wu et al.
ONCOGENE (2019)
Mouse and human urothelial cancer organoids: A tool for bladder cancer research
Jasper Mullenders et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes
Yiao Tan et al.
MEDICAL SCIENCE MONITOR (2019)
A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition
Wenbo Yuan et al.
MOLECULAR ONCOLOGY (2019)
Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling
Xingbo Long et al.
CELL DEATH & DISEASE (2019)
Hydrogen Gas from Inflammation Treatment to Cancer Therapy
Ying Wu et al.
ACS NANO (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Management of metastatic bladder cancer
Rosa Nadal et al.
CANCER TREATMENT REVIEWS (2019)
Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
Hui Guo et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-B survival signals
Chi-Ping Huang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
Yuki Kita et al.
BRITISH JOURNAL OF CANCER (2019)
Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2
Xu Chen et al.
CLINICAL CANCER RESEARCH (2019)
Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer
Kai-Jian Wang et al.
CLINICAL CANCER RESEARCH (2019)
Engineered nanomedicines with enhanced tumor penetration
Jianxun Ding et al.
NANO TODAY (2019)
MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2
Bo Li et al.
JOURNAL OF CANCER (2019)
Protein kinase CK2-dependent aerobic glycolysis-induced lactate dehydrogenase A enhances the migration and invasion of cancer cells
Dae-Kyun Im et al.
SCIENTIFIC REPORTS (2019)
COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Fuli Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Chao Yan et al.
PHARMACOLOGICAL REVIEWS (2018)
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Suk Hyung Lee et al.
CELL (2018)
MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis
Xiaobing Liu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D. Galsky et al.
EUROPEAN UROLOGY (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Panagiotis J. Vlachostergios et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer
Zhi-Rui Lin et al.
CELL DEATH & DISEASE (2018)
Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer
Hui Guo et al.
ADVANCED SCIENCE (2018)
miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a
Jingyi Cao et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
NCCN Guidelines® Insights Bladder Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
Thomas W. Flaig et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Enhanced photo/chemo combination efficiency against bladder tumor by encapsulation of DOX and ZnPC into in situ-formed thermosensitive polymer hydrogel
Zhongming Huang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
An ex vivo Tissue Culture Model for the Assessment of Individualized Drug Responses in Prostate and Bladder Cancer
Arjanneke F. van de Merbel et al.
FRONTIERS IN ONCOLOGY (2018)
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma
Hui Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Wei-Jan Wang et al.
CLINICAL CANCER RESEARCH (2017)
Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer
Xu Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling
Hengbing Wang et al.
ONCOLOGY LETTERS (2017)
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma
Hui Guo et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
Makoto Isono et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
In Situ Nanoreactor for Photosynthesizing H2 Gas To Mitigate Oxidative Stress in Tissue Inflammation
Wei-Lin Wan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness
Qing Zhang et al.
THERANOSTICS (2017)
MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1
Peng Li et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
Felix Wezel et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2017)
The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies
Kalen J. Rimar et al.
CANCER (2017)
Guideline of guidelines: non-muscle-invasive bladder cancer
Solomon L. Woldu et al.
BJU INTERNATIONAL (2017)
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
David J. McConkey et al.
EUROPEAN UROLOGY (2016)
Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscleinvasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
Jinbo Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
Kendall Morrison et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
Lei Wei et al.
ONCOTARGET (2016)
Bladder Cancer and Genetic Mutations
Xiaoying Zhang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Homayoun Zargar et al.
EUROPEAN UROLOGY (2015)
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Elizabeth R. Plimack et al.
EUROPEAN UROLOGY (2015)
Diagnosis and Staging of Bladder Cancer
Maxine Sun et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Lei Miao et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms
Jonine D. Figueroa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
Tetsutaro Hayashi et al.
JOURNAL OF UROLOGY (2015)
Synergistic Antitumor Effect of Triptolide and Cisplatin in Cisplatin Resistant Human Bladder Cancer Cells
Jin-Nyoung Ho et al.
JOURNAL OF UROLOGY (2015)
Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms
Jonine D. Figueroa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Antonina V. Kurtova et al.
NATURE (2015)
MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin
Xin Zhang et al.
PLOS ONE (2015)
A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
Maha Hussain et al.
CANCER (2014)
Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model
Jing Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Understanding nucleotide excision repair and its roles in cancer and ageing
Jurgen A. Marteijn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing
Mei-Chong Wendy Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health
Christophe Morisseau et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities
Michael A. Edelbrock et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2013)
Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells
Fang-Ming Hung et al.
ONCOLOGY REPORTS (2013)
MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status
Ruth L. Vinall et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells
Manabu Tatokoro et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Fibroblast growth factors and their receptors in cancer
Jorgen Wesche et al.
BIOCHEMICAL JOURNAL (2011)
First- and second-line therapy for metastatic urothelial carcinoma of the bladder
F. A. Yafi et al.
Current Oncology (2011)
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Noah M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study
Harry J. M. Groen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The cancer stem cell: premises, promises and challenges
Hans Clevers
NATURE MEDICINE (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
1,25D3 Enhances Antitumor Activity of Gemcitabine and Cisplatin in Human Bladder Cancer Models
Yingyu Ma et al.
CANCER (2010)
Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors
Margaret A. Knowles
FUTURE ONCOLOGY (2008)
Demethylating agent 5-aza-2 '-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin
Donghao Shang et al.
UROLOGY (2008)
The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival
Leonid Schneider et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals
Ikuroh Ohsawa et al.
NATURE MEDICINE (2007)
ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor
Zhiming Yang et al.
NATURE MEDICINE (2007)
Action of epoxyeicosatrienoic acids on cellular function
Arthur A. Spector et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors
Kara R. Schmelzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Clinical relevance of maspin expression in bladder cancer
Wolf-D. Beecken et al.
WORLD JOURNAL OF UROLOGY (2006)
Neoadjuvant chemotherapy in invasive bladder cancer:: Update of a systematic review and meta-analysis of individual patient data
H Abol-Enein et al.
EUROPEAN UROLOGY (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer
CX Pan et al.
ONCOLOGY (2005)
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death
DW Litchfield
BIOCHEMICAL JOURNAL (2003)
Epidermal growth factor receptor and bladder cancer
AJ Colquhoun et al.
POSTGRADUATE MEDICAL JOURNAL (2002)
分享论文
